Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Holding TSE:MDP?
Track your performance easily
MDP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.47 - C$5.56
Previous CloseN/A
Volume43.25K
Average Volume (3M)95.69K
Market Cap
C$121.29M
Enterprise ValueC$113.69M
Total Cash (Recent Filing)$5.23M
Total Debt (Recent Filing)$28.61M
Price to Earnings (P/E)38.6
Beta0.99
Next Earnings
Feb 05, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding24,652,493
10 Day Avg. Volume175,923
30 Day Avg. Volume95,687
Standard Deviation0.24
R-Squared0.12
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.90
Price to Cash Flow (P/CF)3.40
P/FCF Ratio3.60
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.91
Enterprise Value/Ebitda6.90
Forecast
1Y Price Target
C$4.57Price Target Upside14.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Pharmaceuticals Announces $30 Million Public Offering
PremiumCompany Announcements
Medexus Secures FDA Approval for GRAFAPEX, Eyes $100M Revenue Milestone
PremiumCompany Announcements
Medexus Secures BC Reimbursement for Trecondyv
PremiumCompany Announcements
Medexus Pharmaceuticals Secures Deal for Trecondyv in Canada
PremiumCompany Announcements
Medexus Pharmaceuticals Reports Strong Q2 2025 Results
PremiumCompany Announcements
Medexus Shareholders Show Strong Support at Annual MeetingPremiumCompany Announcements
Medexus Awaits FDA Decision on Treosulfan After DelayOptions Prices
Currently, No data available
---
Ownership Overview
9.57% Insiders
0.53% Mutual Funds
0.04% Other Institutional Investors
89.86% Public Companies and
Individual Investors
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.47 and its highest was C$5.56 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Medexus Pharmaceuticals Inc’s market cap is C$121.29M.
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Feb 05, 2025 which is in 7 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported C$0 earnings per share for the quarter, missing the consensus estimate of C$0.03 by -C$0.03.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is 0.04.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 24,652,493 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0 in its last earnings report, missing expectations of C$0.03. Following the earnings report the stock price went down -1.364%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$4.57 (14.54% Upside)
C$4.57 (14.54% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.94%
12-Months-Change
Fundamentals
Return on Equity
8.50%
Trailing 12-Months
Asset Growth
-12.59%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
---
MDP Stock 12 Month Forecast
Average Price Target
C$4.57
▲(14.54% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering MDP
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+43.97%
reiterated a buy rating 4 months ago
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +43.97% per trade.
---